敲除Dock180抑制大鼠H9C2心肌细胞系增殖和促凋亡

目的探讨敲除细胞质移动蛋白1(Dock180)对大鼠H9C2心肌细胞系增殖和凋亡的影响及其机制。方法用CRISPR/Cas9系统构建single guide RNA(sgRNA)Dock180质粒,并将其包装成敲除Dock180重组慢病毒再进行筛选,建立敲除Dock180的H9C2心肌细胞稳定株。实验分为A:阴性慢病毒组(Cas9)、B:敲除Dock180组、C:阴性慢病毒低氧组、D:敲除Dock180低氧组。RT-PCR检测各组细胞Dock180 mRNA表达水平,Western blot检测相关蛋白的表达水平,MTT检测细胞增殖率,流式细胞术检测细胞凋亡率。结果 B组和D组Dock180 mRNA和蛋白无表达;分别较A组和C组,B组和D组p-ERK1/2、Bcl-2蛋白和细胞增殖率均降低(P0.01),Bax蛋白和细胞凋亡率均增加(P0.05,P0.01);较A组,C组Dock180 mRNA和蛋白表达降低,p-ERK1/2、Bcl-2蛋白和细胞增殖率均降低,Bax蛋白和细胞凋亡率均增加(P0.05,P0.01);较B组、D组p-ERK1/2、Bcl-2蛋白和细胞增殖率均降低,Bax蛋白和细胞凋亡率均增加(P0.05,P0.01)。结论敲除Dock180可抑制H9C2心肌细胞增殖,促进细胞凋亡,其作用可能通过p-ERK1/2、Bax和Bcl-2分子介导。     

MicroRNA-26a的表达对急性髓系白血病细胞增殖的影响

目的观察构建has-miR-26a重组慢病毒的表达载体对急性髓系白血病细胞增殖能力的影响。方法构建人MicroRNA-26a慢病毒表达载体(LV-miR-26a-GFP)并感染人急性髓系白血病细胞系NB4;分为未感染组、感染组(感染LV-miR-26a-GFP)以及阴性对照组(感染LV-GFP);用real-time RT-PCR检测miR-26a在NB4细胞内的表达水平,Western blot检测PTEN的表达;用CCK-8法绘制细胞的生长曲线和软琼脂克隆形成实验检测细胞的增殖。结果成功构建miR-26a重组慢病毒的表达载体,感染白血病细胞NB4后,能够成功过表达miR-26a。生长曲线的结果显示与感染LV-GFP阴性对照组和未感染组相比,LV-miR-26a-GFP感染组细胞的增殖速度显著增加(P<0.01),软琼脂克隆形成实验证实了感染LV-miR-26a-GFP的NB4细胞的克隆形成能力(GFP+克隆数为75+10)与阴性对照组(感染LV-GFP)相比(GFP+克隆数为26+5)显著增强(P<0.05)。在NB4细胞中过表达miR-26a后,其靶基因PTEN的表达明显被抑制。结论 MicroRNA-26a的表达可增强急性髓系白血病细胞的增殖能力,促进白血病细胞的增殖。     

慢病毒介导的融合基因SP-TAT-Apoptin对HepG2细胞的作用

目的:将已构建的SP-TAT-Apoptin融合基因真核表达载体包装成感染性慢病毒颗粒,并用病毒颗粒感染肝癌HepG2细胞,测定其诱导凋亡的效率。方法:通过脂质体Li-pofectamine TM2000将SP-TAT-Apoptin融合基因真核表达载体与其他包装质粒共同转导入293FT细胞,包装并收集感染性病毒颗粒,用实时定量PCR法测定病毒滴度,免疫荧光法检测重组慢病毒感染的293FT细胞中SP-TAT-Apoptin融合基因的表达,同时通过流式细胞术(FCM)测定慢病毒感染后HepG2细胞的凋亡率。结果:SP-TAT-Apoptin重组慢病毒感染293FT细胞后,用V5抗原单克隆抗体(mAb)进行免疫荧光化学检测,示SP-TAT-Apoptin融合基因可成功表达于293FT细胞;通过Anexin-VPI法检测示SP-TAT-Apoptin融合基因慢病毒感染肝癌HepG2细胞后可引起细胞凋亡,其凋亡效率明显高于单纯脂质体转染组。结论:成功包装出可表达SP-TAT-Apoptin融合基因且具感染性的慢病毒颗粒,感染HepG2肝癌细胞后可引起其凋亡,为进一步研究融合基因SP-TAT-Apoptin体内治疗效果极其在临床中的应用奠定了基础。     

小鼠BTLA慢病毒表达载体的构建及鉴定

目的 构建小鼠BTLA慢病毒表达载体,并对表达产物进行鉴定.方法 以pET-28a-mBTLA质粒为模板,通过PCR技术构建pMD18-T-mBTLA质粒,将小鼠BTLA基因全长编码序列克隆到慢病毒转移载体,通过脂质体转染293T细胞包装成小鼠BTLA慢病毒颗粒.PCR技术和基因测序对重组质粒进行鉴定.荧光显微镜观察重组慢病毒感染293T细胞形态学变化.RT-PCR和Western blot法鉴定BTLA在重组慢病毒感染293T细胞中的表达.50％组织培养感染剂量法(TCID5o法)检测重组慢病毒滴度.结果 成功构建的pMD18-T-mBTLA质粒和pSL6-mBTLA质粒,经双酶切电泳后均出现大小约为1 kb的条带与mBTLA编码序列的大小相符.基因测序并比对分析进一步证实mBTLA编码序列成功整合到质粒载体.病毒上清PCR扩增和293T细胞形态学观察证实Lenti-mBTLA慢病毒包装成功.TCID50法测定Lenti-mBTLA慢病毒滴度为1.3×108 pfu/mL.RT-PCR和Western blot法证实Lenti-mBTLA慢病毒能有效表达mBTLA mRNA和蛋白质.结论 成功构建了表达小鼠BTLA的慢病毒.     

CKS2 shRNA慢病毒表达载体的构建及其抑制卵巢癌A2780细胞增殖

目的构建靶向CKS2的shRNA慢病毒表达载体,并探讨CKS2敲除对卵巢癌细胞A2780增殖的影响。方法根据siRNA原理设计两对靶向CKS2的shRNA序列(shRNA1、shRNA2)及阴性对照NC shRNA,并克隆到慢病毒表达载体PLKO.1/puro中;将上述质粒转染到293T细胞并包装出慢病毒,用慢病毒感染卵巢癌细胞A2780,实时定量PCR及Western blot检测CKS2表达;MTT法检测A2780细胞增殖;Western blot检测PARP-1的剪切;流式细胞术检测凋亡。结果成功构建CKS2 shRNA慢病毒表达载体能明显降低A2780细胞中CKS2 mRNA及蛋白表达(P0.05);能显著抑制A2780靶向CKS2的shRNA慢病毒表达载体,并包装出慢病毒;感染A2780细胞后,细胞增殖受抑(P0.05);能诱导PARP-1蛋白的剪切及凋亡(P0.05)。结论成功构建靶向CKS2的shRNA慢病毒表达载体,能显著抑制A2780细胞增殖。     

线粒体细胞色素C氧化酶RNAi慢病毒载体的构建

目的：通过构建携带细胞色素C氧化酶基因的RNAi慢病毒载体，获得可供转染的滴度，为下一步研究该基因缺陷在真核细胞中的影响提供物质基础。 方法： 根据线粒体细胞色素C氧化酶设计的两条互补的单链寡核苷酸退火后形成双链，插入到pENTR/U6质粒缺口末端，连接在质粒上生成含RNAi盒的pENTR/U6载体；通过重组作用将pENTR/U6载体的RNAi盒重组到pLenti6/BLOCK-iT-Dest 载体上,构建含U6启动子、靶序列和Pol Ⅲ终止子表达框的MTCOX-I shRNA表达重组体；经脂质体导入293FT细胞，包装成慢病毒，收集病毒上清并检测其滴度。Western blotting检测干扰后细胞内线粒体细胞色素C氧化酶I亚基的表达。 结果： 将目的序列成功连接到载体上，并经测序分析证实载体构建成功；成功包装成高滴度的慢病毒。Western blotting检测结果证实构建的MTCOX-I shRNA表达重组体可显著抑制线粒体细胞色素C氧化酶I亚基的表达。 结论： 成功构建了携带细胞色素C氧化酶基因的RNAi慢病毒载体。     

LMNA突变体HEK293、C2C12模型的构建及其核纤层蛋白A/C亚细胞定位

目的构建A型核纤层蛋白基因(LMNA)野生型、突变体的融合蛋白真核表达载体及LMNA突变体慢病毒载体,研究其在HEK293、C2C12中表达、核纤层蛋白A/C亚细胞定位及细胞核改变。方法将野生型全长LMNA cDNA克隆入pEGFP-N1质粒,构建LMNA野生型质粒pEGFP-N1-LMNA,以野生型质粒为模板构建c.1117A>G定点突变质粒pEGFP-N1-LMNA-I373V。将构建的2种质粒分别转染HEK293、C2C12,用G418筛选转染的C2C12,荧光显微镜下观察细胞核形态及GFP标记的核纤层蛋白A/C亚细胞定位。以pEGFP-N1-LMNA-I373V为模板,构建pHBLV-h-LMNA-I373V-3*flag-GFP-PURO慢病毒,对慢病毒进行包装与滴度测定。pHBLV-GFP-PURO、pHBLV-LMNA-C1117-3*flag-GFP-PURO分别转染C2C12,免疫荧光染色法观察转染后细胞核形态及核纤层蛋白A/C亚细胞定位的改变。结果构建的pEGFP-N1-LMNA、pEGFP-N1-LMNA-I373V及pHBLV-h-LMNA-I373V-3*flag-GFP-PURO测序与目的基因序列完全一致。pEGFP-N1-LMNA转染的HEK293、C2C12核纤层蛋白A/C均匀表达于核膜下,pEGFP-N1-LMNA-I373V转染的HEK293、C2C12内核纤层蛋白A/C核内异常聚集,呈散点样分布;与HEK293相比,C2C12细胞转染效率明显降低。慢病毒转染C2C12的转染率高,突变体慢病毒转染的细胞核形态异常及核纤层蛋白A/C核内分布异常。结论成功构建2种LMNA突变体真核表达载体及突变体转染的HEK293、C2C12模型,为LMNA突变体导致疾病的机制研究奠定科学基础。     

大鼠微小RNA miR-16的克隆及其慢病毒表达载体的构建

目的 克隆微小RNA rno-miR-16,构建其慢病毒表达载体pLV-miR-16并包装成慢病毒颗粒,为进一步研究miR-16的功能奠定了实验基础.方法 从大鼠细胞基因组中用PCR 的方法扩增miR-16 的前体,构建了miR-16的重组表达载体pLV-miR-16,脂质体法将重组慢病毒载体和包装质粒混合物(pPACK-GAG、pPACK-REV和pVSV)共转染包装细胞293TN细胞,包装产生慢病毒,以293TN细胞绿色荧光蛋白(green fluorescent protein,GFP)的表达水平测定病毒滴度.结果 经PCR扩增检测阳性菌落和测序证实,成功构建携带大鼠miR-16基因重组慢病毒载体.倒置荧光显微镜下观察可见包装细胞293TN呈绿色荧光,并测得108＞ifu/ml.结论 成功构建大鼠慢病毒载体pLV-miR-16,为深入研究rno-miR-16的生物学功能奠定了基础.     

PEX慢病毒载体构建及其在293FT细胞中的分泌表达

目的 构建含人MMP-9信号肽-MMP-2-PEX片段的重组慢病毒,并在293FT细胞中分泌表达PEX蛋白.方法 利用RT-PCR、基因重组等技术,构建含MMP-9信号肽-MMP-2-PEX片段的重组慢病毒表达载体pBPLV-signal-PEX,在脂质体介导下与包装质粒(pLP1、pLP2)、包膜质粒(pLP/VSVG)共转染293FT细胞,包装产生慢病毒并进行滴度测定.慢病毒感染2931;3"细胞后,Western印迹法检测293FI"细胞培养上清中PEX的表达.结果 酶切和DNA测序表明慢病毒表达载pBPLV-signal-PEX构建正确,四质粒共转染293FT细胞成功获得慢病毒;慢病毒感染293FT细胞后,在细胞培养卜清中可检测到PEX蛋白的表达.结论 成功构建了含人PEX的重组慢病毒,在体外有效感染293fT细胞并持续分泌表达目的 蛋白,为进一步研究PEX在肿瘤侵袭与转移中的作用提供实验基础.     

Oct4-shRNA慢病毒载体沉默结直肠癌Oct4基因并诱导细胞凋亡的初步研究

目的:探讨Oct4-shRNA慢病毒载体对人结直肠癌SW480细胞Oct4的抑制效率及对细胞凋亡的影响.方法:构建针对Oct4的4对Oct4-shRNA干扰慢病毒载体质粒,用Oct4与GFP融合的过表达质粒分别与4个干扰质粒共转染293T细胞,采用Western blot检测GFP的表达,筛选出干扰效果最好的Oct4-shRNA慢病毒载体,用293T细胞包装后转染SW480细胞,实时荧光定量PCR和Western blot检测Oct4的表达情况,流式细胞仪测定细胞凋亡.结果:与转染阴性对照病毒的对照组相比,转染Oct4-shRNA慢病毒载体的SW480细胞Oct4的mRNA和蛋白表达明显降低(P＜0.01);细胞凋亡明显增加(P＜0.01).结论:Oct4-shRNA慢病毒载体可有效抑制SW480细胞Oct4表达,并显著增加细胞凋亡.     

周期性张应力对C2C12成肌细胞增殖的影响

背景：在力学刺激下,肌肉组织发生改建,其中的成肌过程是一个多阶段的发育过程,细胞外基质的许多信号参与了成肌过程,其中力学信号是肌肉形成和再生的重要外界因子。目前国内外有许多关于周期性张应力刺激成肌细胞凋亡和增殖的报道,但是力学刺激在成肌作用中的具体机制目前还明确。 目的：探讨周期性张应力对C2C12成肌细胞增殖的作用及影响机制。 方法：采用FX4000T应力加载系统对体外培养的C2C12成肌细胞施加10%的周期性张应力,分别作用6,12,24 h。 结果与结论：MTT结果显示,随着加力时间的延长C2C12成肌细胞的增殖情况及S期的细胞周期率逐渐增加,在应力作用12 h时增殖效果最明显(P < 0.05),随后开始降低。Western blot检测显示,C2C12成肌细胞中核转录因子κB蛋白的表达随加力时间增加而不断减少,加力24 h时表达量又开始上升。结果提示,周期性张应力可以诱导C2C12成肌细胞增殖,能够改变其细胞周期,核转录因子κB可能也参与了此调节过程。 中国组织工程研究杂志出版内容重点：组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程全文链接：     

突变型Axin基因在神经胶质瘤细胞系C6中的功能研究

目的研究突变型Axin基因对C6细胞增殖及细胞周期的影响,以期揭示突变型Axin基因是否影响胶质瘤的发生。方法采用噻唑蓝(MTT)比色法绘制细胞生长曲线,应用流式细胞仪(FCM)测定细胞周期的变化,并用平板克隆形成实验对细胞克隆形成能力进行了检测。采用SP法免疫细胞化学染色法检测Ki-67、cyclinD1表达。结果转染突变型Axin基因与转染野生型Axin基因的C6细胞在生长速度,克隆形成能力方面均显著降低,且组间无差别;C6、C6-Vector、C6-Vector-Axin、和C6-Vector-Axin806各组细胞经流式细胞仪检测S期的细胞比例分别为:27.2%、24.8%、18.9%和18.5%;Ki-67及cyclinD1在转染突变型Axin基因与转染野生型Axin基因的C6细胞中表达均降低,且组间无差别。结论突变型Axin基因明显抑制C6细胞的增殖能力,该位点突变可能并不是胶质瘤发生的关键因素。     

The variable,C(H)1, C(H)2 and C(H)3 domains of Ig heavy chain are dispensable for pre-BCR function in transgenic mice

The pre-BCR consists of Ig micro protein, the product of a heavy chain gene assembled by V(D)J recombination in pro-B cells, the surrogate light chains V(pre-B) and lambda 5, and the signaling chains Ig alpha and Ig beta. Signaling by the pre-BCR is a checkpoint required for further maturation of pro-B cells in the adult bone marrow. However, it is currently not known whether an extracellular ligand is required to initiate pre-BCR signaling. We reasoned that if the ectodomain of the pre-BCR is required to interact with a ligand, then a truncated heavy chain protein would not support B cell development. To test this notion, we produced transgenic mice expressing a heavy chain protein whose extracellular domains except for C(H)4 were replaced by an irrelevant Ig superfamily ectodomain from the human CD8 alpha protein. This transgene resulted in pre-BCR-like signaling since it rescued development of pre-B cells in recombinase-activating gene (RAG)1-deficient mice and resulted in allelic exclusion of the endogenous Ig heavy chain gene in RAG-proficient mice. These findings lead us to suggest that the majority of the extracellular region of the pre-BCR is not required for pre-BCR function and, thus, ligand binding is unlikely to be required for pre-BCR function.     

Mosquito cells bind and replicate hepatitis C virus

Several studies have demonstrated some hepatitis C virus (HCV) replication in lymphocyte and hepatocyte cell lines such as in African green monkey Vero cells. The aim of the present study was to select other cell lines able to bind and replicate HCV. Human hepatoma PLC/PRF/5 cells, human lymphoma Namalwa cells, Vero and mosquito AP61 cells were inoculated with HCV-positive plasma, washed six times and examined for the presence of the viral genome at different times post infection, using an RT-PCR method. Binding of HCV to cells was estimated by HCV RNA detection in cells 2 hr after inoculation and in the last wash of these cells. Successive virus passages in cells were carried out. All the cells studied were able to bind HCV but only AP61 and Vero cells provided evidence of replication and production of infectious virus: virus RNA was detected during 28 days post-infection in four successive virus passages. CD81 molecules, a putative HCV receptor, were detected by cytofluorometric analysis. Vero cells express CD81 molecules whereas these molecules were not detected on AP61 cells. It is suggested that other receptors are involved in HCV binding to Vero and AP61 cells.     

Encephalomyocarditis (EMC) virus infection in PC12 and C6 cells

PC12 cells derived rom rat pheochromocytoma and C6 cells derived from rat glioma were infected with 0.3 plaque forming units (PFU)/cell of the D variant of encephalomyocarditis virus (EMC-D), after pretreatment with or without nerve growth factor (NGF). The virus titres in medium and cells were investigated at 6, 12, 24, 48 and 72 h post infection (HPI), and histopathology and viral antigens in cells were examined at 24 and 48 HPI, respectively. As a result, neither viral replication nor light and electron microscopic changes were observed in PC12 cell cultures without NGF-pretreatment. On the contrary, in PC12 cell cultures with NGF-pretreatment, the virus titre prominently increased at 12 HPI, and peaked at 48 HPI. In addition, distinct histological and ultrastructural changes with viral antigens in cells were observed. C6 cells showed similar morphology and susceptibility to EMC-D-infection irrespective of NGF-pretreatment. Namely, the virus titres in C6 cell cultures increased slightly and viral antigens were found in a small number of C6 cells, but there were no evident histological and ultrastructural changes. These results suggest that PC12 cells pretreated with NGF and C6 cells are susceptible to EMC-D infection in vitro.     

The classical and regulatory functions of C1q in immunity and autoimmunity

A classical function of Clq is to bind immune complexes and initiate complement activation producing membrane lytic complexes, opsonins and anaphylatoxins. This classical pathway of complement activation is also elicited when Clq binds some other ligands. Besides complement activation, Clq also regulates cell differentiation, adhesion, migration, activation and survival. Clq deficiency is associated with autoimmunity as well as increased susceptibility to infections. In this article, we discuss the basic properties of Clq, its expression, and classical and regulatory functions. Cellular ＆ Molecular Immunology.     

Btk and phospholipase C gamma 2 can function independently during B cell development

The pre-BCR and the BCR regulate B cell development via a signalosome nucleated by the adaptor protein B cell linker protein (BLNK). Formation of this complex facilitates activation of phospholipase C (PLC) gamma2 by Bruton's tyrosine kinase (Btk). To determine whether Btk and PLCgamma2 also have separate functions, we generated Btk(-/-)PLCgamma2(-/-) mice. They demonstrated a block in development at the pre-B stage and increased pre-BCR surface expression. This phenotype was more severe than that of Btk(-/-) or PLCgamma2(-/-) mice. Although both Btk and PLCgamma2 were required for proliferation of splenic B cells in response to BCR cross-linking, they contributed differently to anti-IgM-induced phosphorylation of ERK. Btk(-/-) and PLCgamma2(-/-) mice each had a reduced frequency of Iglambda-expressing B cells and impaired migration of pre-B cells towards stromal cell-derived factor 1. However, the increase in pre-B cell malignancy that occurs in BLNK(-/-) mice in the absence of Btk was not observed in the absence of PLCgamma2. Thus, Btk and PLCgamma2 act both in concert and independently throughout B cell development.     

Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma

Human aldo-keto reductase family 1 member C3 (AKR1C3) was initially identified as a critical enzyme in reducing 5α-dihydrotestosterone (5α-DHT) to 5α-androstane-3α,17β-diol (3α-diol) and oxidizing 3α-diol to androsterone. Based on these enzymatic activities, AKR1C3 was originally named type 2 3α-hydroxysteroid dehydrogenase (HSD)/type 5 17β-HSD. Additionally, AKR1C3 was demonstrated to be capable of metabolizing other steroids including estrogen and progesterone. Subsequently, AKR1C3 was shown to possess 11-ketoprostaglandin reductase activity in metabolizing prostaglandins and dihydrodiol dehydrogenase x (DDx) activity in metabolizing xenobiotics. Tissue distribution of AKR1C3 has been detected in both sex hormone-dependent organs such as the testis, breast, endometrium, and prostate as well as sex hormone-independent organs including the kidney and urothelium. Although prominent expression of AKR1C isozymes has been reported in human non-small cell lung carcinoma (NSCLC), the expression of AKR1C3 in small cell carcinoma of the lung has not been described. Also, the expression of AKR1C3 in normal lung has not been described. In this study, we demonstrated strong AKR1C3 immunoreactivity in bronchial epithelium but not in bronchial glands or alveolar pneumocytes. Strong AKR1C3 immunoreactivity was also demonstrated in columnar epithelium but only weak immunoreactivity in squamous epithelium of the gastrointestinal junction. Although AKR1C3 immunoreactivity was absent in small cell carcinoma of the lung, positive AKR1C3 immunoreactivity was extensively present in both adenocarcinoma and squamous cell carcinoma arising from the lung and the gastroesophageal junction. AKR1C3 may serve as an adjunct marker for differentiating small cell carcinoma from NSCLC. However, roles of AKR1C3 in adenocarcinoma, squamous cell carcinoma, and small cell carcinoma pathogenesis require further studies.     

Adaptive control of intracellular Ca2+ release in C2C12 mouse myotubes

Laser scanning confocal imaging was used to monitor release of Ca²⁺ from localized regions in a skeletal muscle cell line with sparsely distributed Ca²⁺ release sites. The goal was to distinguish between two schemes proposed to explain the phenomenon of “quantal” Ca²⁺ release from caffeine-sensitive Ca²⁺ stores in muscle and other tissues: (1) all-or-none (true quantal) Ca²⁺ release from functionally discrete stores that have different sensitivities to caffeine; or (2) adaptive behavior of individual release sites, each responding transiently and repeatedly to incremental caffeine doses. Our results showed that Ca²⁺ release induced by K⁺ or caffeine occurs in discrete loci within the cell. The image areas and fluorescence intensities of some of these evoked local signals were similar to those of Ca²⁺ sparks that were observed under resting conditions and which are believed to be due to spontaneous activation of single release units. In contrast to the expectations imposed by quantal models, incremental doses of caffeine activated the same sets of release sites throughout the cell. Ca²⁺ release, at a given site, triggered by a submaximal dose of caffeine was transient and could be reactivated by addition of a higher caffeine dose, showing the same type of adaptive behavior as measured globally from larger areas of the cell. These results suggest that incremental Ca²⁺ release is accounted for by adaptive behavior of individual Ca²⁺ release sites. Received: 9 August 1995/Received in revised form and accepted: 13 October 1995     

Z-HL16C细胞建株的研究

目的Z-HL16C建株后对其性质和应用的研究。方法将该细胞传代冻存再复苏、扩大应用，进而对其性质进行鉴定。结果类上皮细胞，形态均一、界限清晰、有立体感。经传代、培养、冻存至今已10年，复苏率90％以上。该细胞株对脊髓灰质炎，柯萨奇A-B，艾柯病毒，甲、乙型流感病毒，1～3型副流感病毒，合胞病毒，麻疹病毒，风疹病毒，腺病毒（2，3，7，11型），1—2型单纯疱疹病毒，水痘带状疱疹病毒及巨细胞病毒均敏感，经鉴定为癌变细胞系。结论Z-HL16C为稳定的、对病毒广谱敏感的癌变细胞系。